4th Quarter - Amendment

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$490,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2021 $490,000 Replaced
4th Quarter - Amendment Apr 20, 2021 $490,000 Replaced
4th Quarter - Amendment (this page) Jan 6, 2022 $490,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

Issues relating to requirements for ride hailing vehicles and companies, S. 1871 and H.R. 4686, Samis Law. Issues relating to highway/transportation reauthorization and appropriations, including H.R. 2, the Moving Forward Act.

LobbyistCovered position, as disclosed
OKEYSHA BROOKS-COLEY —
STEPHANIE KRENRICH —

Contacted: Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); U.S. Agency for International Development (USAID); Small Business Administration (SBA); White House Office; Centers For Disease Control & Prevention (CDC); Federal Reserve System; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Federal Trade Commission (FTC); Transportation, Dept of (DOT); SENATE; Labor, Dept of (DOL); Food & Drug Administration (FDA); Energy, Dept of; Treasury, Dept of; Veterans Affairs, Dept of (VA); Natl Institutes of Health (NIH)

Bills named: H.R. 4686 (116th), S. 1871 (116th), H.R. 2 (116th)

Medicare/Medicaid MMM

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act HR 1948, Lymphedema Treatment Act; HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trials; Senate introduction (no bill number just yet); Issues related to Medicaid Non-Emergency Medical Transportation; and Issues related to Chimeric antigen receptor (CAR) T-cell therapy and reimbursement. HR 2477, Beneficiary Enrollment Notification and Eligibility Simplification Act (BENES) Regulatory issues related to Medicaid and value-based payment HR 7663, Protecting Access to Post COVID 19 Telehealth Act of 2020 The Access to Genetic Counselor Services Act of 2019, HR 3235 Advocacy w. CMS related to state Medicaid 1115 waiver approvals Multi-Cancer Early Detection Screening Coverage Act of 2020, HR 8845

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
STEPHANIE KRENRICH —
CAROLINE POWERS —
PHYLICIA L WOODS —

Contacted: Labor, Dept of (DOL); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Treasury, Dept of; Energy, Dept of; White House Office; Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Federal Reserve System; U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Transportation, Dept of (DOT); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Small Business Administration (SBA); Federal Trade Commission (FTC); SENATE; State, Dept of (DOS)

Bills named: H.R. 913 (116th), H.R. 6800 (116th), H.R. 1948 (116th), H.R. 1570 (116th), H.R. 3235 (116th), H.R. 2477 (116th), H.R. 7663 (116th), S. 668 (116th), H.R. 8845 (116th)

Budget/Appropriations BUD

FY 2021 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; issues related to global health funding of the World Health Organization and for cervical cancer screening & treatment and HPV vaccination; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE). HR 133, Consolidated Appropriations Act, 2021 HR 8337, Making continuing appropriations for fiscal year 2021, and for other purposes HR 925, the HEROES Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act H.R.7610, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021 S 178, Legislative vehicle for the Protect Act

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
STEPHANIE KRENRICH —
CAROLINE POWERS —

Contacted: Federal Trade Commission (FTC); Transportation, Dept of (DOT); Centers For Disease Control & Prevention (CDC); Small Business Administration (SBA); Environmental Protection Agency (EPA); White House Office; State, Dept of (DOS); Natl Institutes of Health (NIH); Treasury, Dept of; Federal Reserve System; SENATE; Energy, Dept of; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Defense, Dept of (DOD)

Bills named: H.R. 133 (116th), H.R. 925 (116th), H.R. 748 (116th), H.R. 6704 (116th), H.R. 6800 (116th), H.R. 7610 (116th), H.R. 8337 (116th)

Tobacco TOB

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R, 7286 and S 4524, the Quit Because of COVID-19 Act:

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
CAROLINE POWERS —

Contacted: Environmental Protection Agency (EPA); Transportation, Dept of (DOT); Federal Trade Commission (FTC); Federal Reserve System; Defense, Dept of (DOD); Small Business Administration (SBA); Centers For Disease Control & Prevention (CDC); White House Office; Labor, Dept of (DOL); Energy, Dept of; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Veterans Affairs, Dept of (VA); Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Treasury, Dept of; Food & Drug Administration (FDA); SENATE

Taxation/Internal Revenue Code TAX

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act. Issues related to economic relief for nonprofit organizations and charitable giving incentives included in H.R. 6408, the Saving the Organizations that Serve (SOS) America Act, H.R.3814, the Reviving the Economy Sustainably Towards A Recovery in Twenty-twenty Act or the RESTART Act, S.3747, the WORK NOW Act, S.4032 and H.R.7324, the Universal Giving Pandemic Response Act, charitable giving amendment (S.Amdt. 1566) to the CARES Act, S.4001and S.4209, the Protecting Nonprofits from Catastrophic Cash Flow Strain Act of 2020, H.R. 7066, the Reopening America by Supporting Workers and Businesses Act of 2020, the Help Charities Protect Communities Act (introduction pending), S. 178 (legislative vehicle for the Protect Act), and HR 925, The Heroes Act. Medical expense deduction - lowering the percentage to 7.5%

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
STEPHANIE KRENRICH —
CAROLINE POWERS —
PHYLICIA L WOODS —

Contacted: Defense, Dept of (DOD); U.S. Agency for International Development (USAID); SENATE; Treasury, Dept of; Transportation, Dept of (DOT); Food & Drug Administration (FDA); State, Dept of (DOS); White House Office; Energy, Dept of; Federal Reserve System; Labor, Dept of (DOL); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Small Business Administration (SBA); Centers For Disease Control & Prevention (CDC); Federal Trade Commission (FTC)

Bills named: S. 1257 (116th), H.R. 7066 (116th), S. 3747 (116th), H.R. 3814 (116th), S. 4209 (116th), S. 4032 (116th), H.R. 3832 (116th), H.R. 7324 (116th), H.R. 6408 (116th), H.R. 925 (116th), S. 178 (116th)

Health Issues HCR

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
STEPHANIE KRENRICH —
CAROLINE POWERS —
PHYLICIA L WOODS —

Contacted: Environmental Protection Agency (EPA); Labor, Dept of (DOL); Federal Trade Commission (FTC); Federal Reserve System; State, Dept of (DOS); Natl Institutes of Health (NIH); White House Office; Defense, Dept of (DOD); Transportation, Dept of (DOT); Treasury, Dept of; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Small Business Administration (SBA); Energy, Dept of; U.S. Agency for International Development (USAID); Food & Drug Administration (FDA)

Bills named: H.R. 6666 (116th), H.Res. 14 (116th), H.R. 6800 (116th), H.R. 6556 (116th), S. 4315 (116th), S. 2032 (116th), H.R. 6102 (116th), S. 2497 (116th), H.R. 1028 (116th), S. 4010 (116th), S.Res. 223 (116th), H.R. 647 (116th), H.R. 2222 (116th), H.R. 4439 (116th), H.R. 1966 (116th), H.Res. 1125 (116th), S. 1107 (116th), S. 3404 (116th), H.R. 6514 (116th), S. 2424 (116th), H.R. 4078 (116th), S. 2080 (116th), H.R. 1730 (116th), H.Res. 282 (116th), H.R. 1425 (116th), S. 1719 (116th), H.R. 1409 (116th), H.R. 3630 (116th), S. 741 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.